![]() |
Palbociclib expanded access program now open to eligible U.S. patients with HR+, HER2
Pfizer Inc. has announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib.
More... |
| All times are GMT -7. The time now is 04:05 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021